<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266810</url>
  </required_header>
  <id_info>
    <org_study_id>P500-0514</org_study_id>
    <nct_id>NCT02266810</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>The PROGRESS Study: Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implants Following Surgical Opening of the Frontal Sinus for Chronic Sinusitis: A Randomized Blinded Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intersect ENT</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Advance Research Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Intersect ENT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the PROGRESS Study is to assess the safety and efficacy of the Propel Mini
      and Propel Nova steroid-eluting Sinus Implants when placed in the frontal sinus opening
      following frontal sinus surgery in patients with chronic sinusitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, blinded, controlled, multicenter study enrolling two
      consecutive cohorts of up to 80 patients each (Propel Mini cohort followed by Propel Nova
      cohort). The study patients will undergo implant placement on one side following ESS that
      includes bilateral frontal sinus surgery by traditional surgical technique or balloon
      dilation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Sinuses That Require Post-operative Interventions (Propel Mini Cohort)</measure>
    <time_frame>Day 30</time_frame>
    <description>The reduction in need for post-operative interventions at Day 30, as determined by an independent blinded sinus surgeon based on video-endoscopy reviews.
Need for Post-Operative Intervention is a composite endpoint that includes: surgical intervention required to debride obstructive adhesions or scar tissue formation in the Frontal sinus opening(defined as grade 2 or 3 on the adhesion/scarring scale), and/or oral steroid intervention warranted to resolve recurrent inflammation and polypoid edema in the frontal recess/FSO (Yes/No response).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Sinuses That Require Post-operative Interventions (Propel Nova Cohort)</measure>
    <time_frame>Day 30</time_frame>
    <description>The reduction in need for post-operative interventions at Day 30, as determined by an independent blinded sinus surgeon based on video-endoscopy reviews.
Need for Post-Operative Intervention is a composite endpoint that includes: surgical intervention required to debride obstructive adhesions or scar tissue formation in the Frontal sinus opening(defined as grade 2 or 3 on the adhesion/scarring scale), and/or oral steroid intervention warranted to resolve recurrent inflammation and polypoid edema in the frontal recess/FSO (Yes/No response).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for Post-operative Interventions (Propel Mini Cohort)</measure>
    <time_frame>Day 30</time_frame>
    <description>Need for post-operative interventions by clinical investigators at Day 30
Need for Post-Operative Intervention is a composite endpoint that includes: surgical intervention required to debride obstructive adhesions or scar tissue formation in the FSO (defined as grade 2 or 3 on the adhesion/scarring scale), and/or oral steroid intervention warranted to resolve recurrent inflammation and polypoid edema in the frontal recess/FSO (Yes/No response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Surgical Interventions (Propel Mini Cohort)</measure>
    <time_frame>Day 30</time_frame>
    <description>Need for Surgical Interventions by clinical investigators at Day 30.
Need for surgical interventions was prospectively defined as Adhesion/scarring grades of 2 and 3.
Adhesions/Scarring was assessed based on a 4-point scale as follows:
0= No visible granulation/scarring in the FSO
Minimal amount of granulation, scarring or contraction observed but not obstructing the FSO (intervention not warranted)
Moderate amount of obstructive granulation, scarring or contraction present in the FSO (intervention is warranted)
Significant amount of scarring or contraction causing obstruction of the FSO requiring intervention (likely to compromise patency if not removed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation (Propel Mini Cohort)</measure>
    <time_frame>Day 30</time_frame>
    <description>The degree of inflammation present in the frontal recess/FSO was evaluated by clinical investigators using a 100-mm VAS ranging from 0 defined as no visible inflammation to 100 defined as severe inflammation, involving extensive erythema, edema, or polyposis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occlusion/Restenosis (Propel Mini Cohort)</measure>
    <time_frame>Day 30</time_frame>
    <description>Patency of the FSO was assessed by clinical investigators endoscopically on a 3-point grading scale as follows:
0=Patent
Restenosed/Partially Occluded
Occluded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Post-operative Interventions (Propel Nova Cohort)</measure>
    <time_frame>Day 30</time_frame>
    <description>Need for post-operative interventions by clinical investigators at Day 30.
Need for Post-Operative Intervention is a composite endpoint that includes: surgical intervention required to debride obstructive adhesions or scar tissue formation in the FSO (defined as grade 2 or 3 on the adhesion/scarring scale by investigators), and/or oral steroid intervention warranted to resolve recurrent inflammation and polypoid edema in the frontal recess/FSO (Yes/No response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Surgical Interventions (Propel Nova Cohort)</measure>
    <time_frame>Day 30</time_frame>
    <description>Need for Surgical Interventions by clinical investigators at Day 30
Need for Surgical Interventions by clinical investigators at Day 30.
Need for surgical interventions was prospectively defined as Adhesion/scarring grades of 2 and 3.
Adhesions/Scarring was assessed based on a 4-point scale as follows:
0= No visible granulation/scarring in the FSO
Minimal amount of granulation, scarring or contraction observed but not obstructing the FSO (intervention not warranted)
Moderate amount of obstructive granulation, scarring or contraction present in the FSO (intervention is warranted)
Significant amount of scarring or contraction causing obstruction of the FSO requiring intervention (likely to compromise patency if not removed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation (Propel Nova Cohort)</measure>
    <time_frame>Day 30</time_frame>
    <description>The degree of inflammation present in the frontal recess/FSO was evaluated by clinical investigators using a 100-mm VAS ranging from 0 defined as no visible inflammation to 100 defined as severe inflammation, involving extensive erythema, edema, or polyposis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occlusion/Restenosis (Propel Nova Cohort)</measure>
    <time_frame>Day 30</time_frame>
    <description>Patency of the FSO was assessed by clinical investigators endoscopically on a 3-point grading scale as follows:
0=Patent
Restenosed/Partially Occluded
Occluded</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Chronic Sinusitis</condition>
  <arm_group>
    <arm_group_label>PROPEL Mini Sinus Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propel Mini placed in frontal sinus opening following ESS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sinus Surgery alone: cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sinus Surgery only: cohort 1: ESS with standard post-operative care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPEL Nova Sinus Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propel Nova placed in frontal sinus opening following ESS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sinus Surgery alone: cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sinus Surgery only: cohort 2: ESS with standard post-operative care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PROPEL Mini Sinus Implant.</intervention_name>
    <description>Placement of sinus implant following frontal sinus surgery</description>
    <arm_group_label>PROPEL Mini Sinus Implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sinus Surgery alone</intervention_name>
    <description>Sinus surgery only, without implant placement</description>
    <arm_group_label>Sinus Surgery alone: cohort 1</arm_group_label>
    <arm_group_label>Sinus Surgery alone: cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Propel Nova Sinus Implant</intervention_name>
    <description>Placement of sinus implant following frontal sinus surgery</description>
    <arm_group_label>PROPEL Nova Sinus Implant</arm_group_label>
    <other_name>PROPEL contour Sinus Implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has CRS confirmed by CT scan and defined as symptoms lasting longer than 12
             consecutive weeks in duration with inflammation of the mucosa of the nose and
             paranasal sinuses.

          -  Patient has a clinical indication for and has consented to ESS including bilateral
             frontal sinus surgery.

          -  Chronic sinusitis diagnosis confirmed and documented by CT scan within 6 months of the
             procedure.

          -  Patient has bilateral disease in both frontal sinuses confirmed by Lund-Mackay score
             of â‰¥1 on each side.

          -  Planned sinus surgery includes bilateral ethmoidectomy (if judged necessary) and
             frontal sinus enlargement using Draf II (A or B) dissection or balloon dilation, with
             minimum of 5-mm diameter opening created.

          -  Technique used for frontal sinus surgery is the same on both sides (e.g. surgical
             dissection alone bilaterally, balloon dilation alone bilaterally, or both bilaterally)

          -  Septoplasty for access to the ostio-meatal complex is permitted.

          -  ESS including bilateral frontal sinus surgery has been successfully completed without
             significant complication that, in the opinion of the investigator, would confound
             study results, and the patient's anatomy remains amenable to implant placement.

        Exclusion Criteria:

          -  Known history of immune deficiency such as immunoglobin G or A subclass deficiency, or
             Human Immunodeficiency Virus (HIV)

          -  Oral-steroid dependent condition such as chronic obstructive pulmonary disease (COPD)
             or asthma or other condition

          -  Known history of allergy or intolerance to corticosteroids or mometasone furoate

          -  Clinical evidence of acute bacterial sinusitis

          -  Clinical evidence or suspicion of invasive fungal sinusitis (e.g., bone erosion on CT
             scan, necrotic sinus tissue)

          -  Active viral illness

          -  Concurrent condition requiring active chemotherapy and/or immunotherapy management for
             the disease

          -  Clinical evidence of disease or condition expected to compromise survival or ability
             to complete follow-up assessments during the 90 day follow-up period

          -  Currently participating in another clinical trial

          -  History of insulin dependent diabetes mellitus

          -  Patient has previously undergone ESS and experienced a CSF leak or has compromised
             vision as a result of a complication in a prior ESS procedure

          -  Significant complication during the current frontal sinus surgery procedure such as
             excessive blood loss, CSF leak or punctured lamina papyracea

          -  Current ESS including frontal sinus surgery is aborted for any reason.

          -  At least one side is not amenable for implant placement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy L. Smith, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amber U. Luong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sacramento Ear, Nose and Throat</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breathe Clear Institute of Sinus and Allergy Relief</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Connecticut Center for Advanced ENT Care</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Faculty Associates</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENT of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced ENT and Allergy</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany ENT and Allergy</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Smith TL, Singh A, Luong A, Ow RA, Shotts SD, Sautter NB, Han JK, Stambaugh J, Raman A. Randomized controlled trial of a bioabsorbable steroid-releasing implant in the frontal sinus opening. Laryngoscope. 2016 Dec;126(12):2659-2664. doi: 10.1002/lary.26140. Epub 2016 Jul 1.</citation>
    <PMID>27363723</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <results_first_submitted>June 10, 2016</results_first_submitted>
  <results_first_submitted_qc>October 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2017</results_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PROPEL Mini Sinus Implant</title>
          <description>This study will use an intra-patient design. Each patient will undergo placement of one implant. The untreated side will represent the control. The side of placement will be randomly assigned.
PROPEL Mini Sinus Implant: Placement of sinus implant following frontal sinus surgery</description>
        </group>
        <group group_id="P2">
          <title>PROPEL Nova Sinus Implant</title>
          <description>This study will use an intra-patient design. Each patient will undergo placement of one implant. The untreated side will represent the control. The side of placement will be randomly assigned.
PROPEL Nova Sinus Implant: Placement of sinus implant following frontal sinus surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80">sinus sides</participants>
                <participants group_id="P2" count="80">sinus sides</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79">sinus sides</participants>
                <participants group_id="P2" count="79">sinus sides</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is an intra-patient design where one sinus side of the patient is randomized to receive the treatment while the contralateral sinus side acts as the control.</population>
      <group_list>
        <group group_id="B1">
          <title>PROPEL Mini Sinus Implant and No Implant Cohort 1</title>
          <description>This study will use an intra-patient design. Each patient will undergo placement of one implant. The untreated side will represent the control. The side of placement will be randomly assigned.
PROPEL Mini or Nova Sinus Implant.: Placement of sinus implant following frontal sinus surgery</description>
        </group>
        <group group_id="B2">
          <title>PROPEL Nova Sinus Implant and No Implant Cohort 2</title>
          <description>This study will use an intra-patient design. Each patient will undergo placement of one implant. The untreated side will represent the control. The side of placement will be randomly assigned.
PROPEL Mini or Nova Sinus Implant.: Placement of sinus implant following frontal sinus surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="13.91"/>
                    <measurement group_id="B2" value="49.5" spread="13.36"/>
                    <measurement group_id="B3" value="49.7" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Sinuses That Require Post-operative Interventions (Propel Mini Cohort)</title>
        <description>The reduction in need for post-operative interventions at Day 30, as determined by an independent blinded sinus surgeon based on video-endoscopy reviews.
Need for Post-Operative Intervention is a composite endpoint that includes: surgical intervention required to debride obstructive adhesions or scar tissue formation in the Frontal sinus opening(defined as grade 2 or 3 on the adhesion/scarring scale), and/or oral steroid intervention warranted to resolve recurrent inflammation and polypoid edema in the frontal recess/FSO (Yes/No response).</description>
        <time_frame>Day 30</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>PROPEL Mini Sinus Implant</title>
            <description>Propel Mini placed in frontal sinus opening following ESS
PROPEL Mini Sinus Implant.: Placement of sinus implant following frontal sinus surgery</description>
          </group>
          <group group_id="O2">
            <title>Sinus Surgery Only: Cohort 1</title>
            <description>Sinus surgery with standard post-operative care.
Sinus Surgery alone: Sinus surgery only, without implant placement</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Sinuses That Require Post-operative Interventions (Propel Mini Cohort)</title>
          <description>The reduction in need for post-operative interventions at Day 30, as determined by an independent blinded sinus surgeon based on video-endoscopy reviews.
Need for Post-Operative Intervention is a composite endpoint that includes: surgical intervention required to debride obstructive adhesions or scar tissue formation in the Frontal sinus opening(defined as grade 2 or 3 on the adhesion/scarring scale), and/or oral steroid intervention warranted to resolve recurrent inflammation and polypoid edema in the frontal recess/FSO (Yes/No response).</description>
          <population>ITT population</population>
          <units>percent sinuses requiring intervention</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" lower_limit="27.1" upper_limit="51.5"/>
                    <measurement group_id="O2" value="62.7" lower_limit="50.0" upper_limit="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Sinuses That Require Post-operative Interventions (Propel Nova Cohort)</title>
        <description>The reduction in need for post-operative interventions at Day 30, as determined by an independent blinded sinus surgeon based on video-endoscopy reviews.
Need for Post-Operative Intervention is a composite endpoint that includes: surgical intervention required to debride obstructive adhesions or scar tissue formation in the Frontal sinus opening(defined as grade 2 or 3 on the adhesion/scarring scale), and/or oral steroid intervention warranted to resolve recurrent inflammation and polypoid edema in the frontal recess/FSO (Yes/No response).</description>
        <time_frame>Day 30</time_frame>
        <population>Of the 80 patients who had their endoscopy recorded at day 30 for grading by independent reviewer; 19 patients could not be included in the test due to missing data. Data were considered missing if the independent reviewer could not grade a video on one or both treatment sinus sides.</population>
        <group_list>
          <group group_id="O1">
            <title>PROPEL Nova Sinus Implant</title>
            <description>Propel Nova placed in frontal sinus opening following ESS
Propel Nova Sinus Implant: Placement of sinus implant following frontal sinus surgery</description>
          </group>
          <group group_id="O2">
            <title>Sinus Surgery Only: Cohort 2</title>
            <description>Sinus surgery with standard post-operative care.
Sinus Surgery alone: Sinus surgery only, without implant placement</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Sinuses That Require Post-operative Interventions (Propel Nova Cohort)</title>
          <description>The reduction in need for post-operative interventions at Day 30, as determined by an independent blinded sinus surgeon based on video-endoscopy reviews.
Need for Post-Operative Intervention is a composite endpoint that includes: surgical intervention required to debride obstructive adhesions or scar tissue formation in the Frontal sinus opening(defined as grade 2 or 3 on the adhesion/scarring scale), and/or oral steroid intervention warranted to resolve recurrent inflammation and polypoid edema in the frontal recess/FSO (Yes/No response).</description>
          <population>Of the 80 patients who had their endoscopy recorded at day 30 for grading by independent reviewer; 19 patients could not be included in the test due to missing data. Data were considered missing if the independent reviewer could not grade a video on one or both treatment sinus sides.</population>
          <units>percentage sinus requiring intervention</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="4.7" upper_limit="22.2"/>
                    <measurement group_id="O2" value="32.8" lower_limit="21.3" upper_limit="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Post-operative Interventions (Propel Mini Cohort)</title>
        <description>Need for post-operative interventions by clinical investigators at Day 30
Need for Post-Operative Intervention is a composite endpoint that includes: surgical intervention required to debride obstructive adhesions or scar tissue formation in the FSO (defined as grade 2 or 3 on the adhesion/scarring scale), and/or oral steroid intervention warranted to resolve recurrent inflammation and polypoid edema in the frontal recess/FSO (Yes/No response).</description>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PROPEL Mini Sinus Implant</title>
            <description>This study will use an intra-patient design. Each patient will undergo placement of one implant. The untreated side will represent the control. The side of placement will be randomly assigned.
PROPEL Mini Sinus Implant: Placement of sinus implant following frontal sinus surgery</description>
          </group>
          <group group_id="O2">
            <title>Sinus Surgery Only: Cohort 1</title>
            <description>This study will use an intra-patient design. Each patient will undergo placement of one implant. The untreated side will represent the control. The side of placement will be randomly assigned.
Sinus Surgery only: Sinus surgery only, without implant placement</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Post-operative Interventions (Propel Mini Cohort)</title>
          <description>Need for post-operative interventions by clinical investigators at Day 30
Need for Post-Operative Intervention is a composite endpoint that includes: surgical intervention required to debride obstructive adhesions or scar tissue formation in the FSO (defined as grade 2 or 3 on the adhesion/scarring scale), and/or oral steroid intervention warranted to resolve recurrent inflammation and polypoid edema in the frontal recess/FSO (Yes/No response).</description>
          <units>percentage of evaluable sinuses</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>sinus sides</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sinus sides</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="9.1" upper_limit="26.5"/>
                    <measurement group_id="O2" value="41.8" lower_limit="30.8" upper_limit="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Surgical Interventions (Propel Mini Cohort)</title>
        <description>Need for Surgical Interventions by clinical investigators at Day 30.
Need for surgical interventions was prospectively defined as Adhesion/scarring grades of 2 and 3.
Adhesions/Scarring was assessed based on a 4-point scale as follows:
0= No visible granulation/scarring in the FSO
Minimal amount of granulation, scarring or contraction observed but not obstructing the FSO (intervention not warranted)
Moderate amount of obstructive granulation, scarring or contraction present in the FSO (intervention is warranted)
Significant amount of scarring or contraction causing obstruction of the FSO requiring intervention (likely to compromise patency if not removed)</description>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PROPEL Mini Sinus Implant</title>
            <description>Propel Mini placed in frontal sinus opening following ESS
PROPEL Mini Sinus Implant.: Placement of sinus implant following frontal sinus surgery</description>
          </group>
          <group group_id="O2">
            <title>Sinus Surgery Only: Cohort 1</title>
            <description>Sinus surgery with standard post-operative care.
Sinus Surgery alone: Sinus surgery only, without implant placement</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Surgical Interventions (Propel Mini Cohort)</title>
          <description>Need for Surgical Interventions by clinical investigators at Day 30.
Need for surgical interventions was prospectively defined as Adhesion/scarring grades of 2 and 3.
Adhesions/Scarring was assessed based on a 4-point scale as follows:
0= No visible granulation/scarring in the FSO
Minimal amount of granulation, scarring or contraction observed but not obstructing the FSO (intervention not warranted)
Moderate amount of obstructive granulation, scarring or contraction present in the FSO (intervention is warranted)
Significant amount of scarring or contraction causing obstruction of the FSO requiring intervention (likely to compromise patency if not removed)</description>
          <units>percentage of evaluable sinuses</units>
          <param>Number</param>
          <units_analyzed>sinus sides</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sinus sides</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation (Propel Mini Cohort)</title>
        <description>The degree of inflammation present in the frontal recess/FSO was evaluated by clinical investigators using a 100-mm VAS ranging from 0 defined as no visible inflammation to 100 defined as severe inflammation, involving extensive erythema, edema, or polyposis.</description>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PROPEL Mini Sinus Implant</title>
            <description>Propel Mini placed in frontal sinus opening following ESS
PROPEL Mini Sinus Implant.: Placement of sinus implant following frontal sinus surgery</description>
          </group>
          <group group_id="O2">
            <title>Sinus Surgery Alone: Cohort 1</title>
            <description>Sinus Surgery only: cohort 1: ESS with standard post-operative care.
Sinus Surgery alone: Sinus surgery only, without implant placement</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation (Propel Mini Cohort)</title>
          <description>The degree of inflammation present in the frontal recess/FSO was evaluated by clinical investigators using a 100-mm VAS ranging from 0 defined as no visible inflammation to 100 defined as severe inflammation, involving extensive erythema, edema, or polyposis.</description>
          <units>100-mm VAS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>sinus sides</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sinus sides</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" spread="27.02"/>
                    <measurement group_id="O2" value="41.3" spread="29.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occlusion/Restenosis (Propel Mini Cohort)</title>
        <description>Patency of the FSO was assessed by clinical investigators endoscopically on a 3-point grading scale as follows:
0=Patent
Restenosed/Partially Occluded
Occluded</description>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PROPEL Mini Sinus Implant</title>
            <description>Propel Mini placed in frontal sinus opening following ESS
PROPEL Mini Sinus Implant.: Placement of sinus implant following frontal sinus surgery</description>
          </group>
          <group group_id="O2">
            <title>Sinus Surgery Only: Cohort 1</title>
            <description>Sinus surgery with standard post-operative care.
Sinus Surgery alone: Sinus surgery only, without implant placement</description>
          </group>
        </group_list>
        <measure>
          <title>Occlusion/Restenosis (Propel Mini Cohort)</title>
          <description>Patency of the FSO was assessed by clinical investigators endoscopically on a 3-point grading scale as follows:
0=Patent
Restenosed/Partially Occluded
Occluded</description>
          <units>percentage of evaluable sinuses</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>sinus sides</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sinus sides</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="12.5" upper_limit="31.9"/>
                    <measurement group_id="O2" value="46.1" lower_limit="34.5" upper_limit="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Post-operative Interventions (Propel Nova Cohort)</title>
        <description>Need for post-operative interventions by clinical investigators at Day 30.
Need for Post-Operative Intervention is a composite endpoint that includes: surgical intervention required to debride obstructive adhesions or scar tissue formation in the FSO (defined as grade 2 or 3 on the adhesion/scarring scale by investigators), and/or oral steroid intervention warranted to resolve recurrent inflammation and polypoid edema in the frontal recess/FSO (Yes/No response).</description>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PROPEL Nova Sinus Implant</title>
            <description>This study will use an intra-patient design. Each patient will undergo placement of one implant. The untreated side will represent the control. The side of placement will be randomly assigned.
PROPEL Nova Sinus Implant: Placement of sinus implant following frontal sinus surgery</description>
          </group>
          <group group_id="O2">
            <title>Sinus Surgery Only: Cohort 2</title>
            <description>This study will use an intra-patient design. Each patient will undergo placement of one implant. The untreated side will represent the control. The side of placement will be randomly assigned.
Sinus Surgery only: Sinus surgery only, without implant placement</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Post-operative Interventions (Propel Nova Cohort)</title>
          <description>Need for post-operative interventions by clinical investigators at Day 30.
Need for Post-Operative Intervention is a composite endpoint that includes: surgical intervention required to debride obstructive adhesions or scar tissue formation in the FSO (defined as grade 2 or 3 on the adhesion/scarring scale by investigators), and/or oral steroid intervention warranted to resolve recurrent inflammation and polypoid edema in the frontal recess/FSO (Yes/No response).</description>
          <units>percentage of evaluable sinuses</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>sinus sides</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sinus sides</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="8.6" upper_limit="26.3"/>
                    <measurement group_id="O2" value="33.3" lower_limit="22.9" upper_limit="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Surgical Interventions (Propel Nova Cohort)</title>
        <description>Need for Surgical Interventions by clinical investigators at Day 30
Need for Surgical Interventions by clinical investigators at Day 30.
Need for surgical interventions was prospectively defined as Adhesion/scarring grades of 2 and 3.
Adhesions/Scarring was assessed based on a 4-point scale as follows:
0= No visible granulation/scarring in the FSO
Minimal amount of granulation, scarring or contraction observed but not obstructing the FSO (intervention not warranted)
Moderate amount of obstructive granulation, scarring or contraction present in the FSO (intervention is warranted)
Significant amount of scarring or contraction causing obstruction of the FSO requiring intervention (likely to compromise patency if not removed)</description>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PROPEL Nova Sinus Implant</title>
            <description>Propel Nova placed in frontal sinus opening following ESS
PROPEL Nova Sinus Implant.: Placement of sinus implant following frontal sinus surgery</description>
          </group>
          <group group_id="O2">
            <title>Sinus Surgery Only: Cohort 2</title>
            <description>Sinus surgery with standard post-operative care.
Sinus Surgery alone: Sinus surgery only, without implant placement</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Surgical Interventions (Propel Nova Cohort)</title>
          <description>Need for Surgical Interventions by clinical investigators at Day 30
Need for Surgical Interventions by clinical investigators at Day 30.
Need for surgical interventions was prospectively defined as Adhesion/scarring grades of 2 and 3.
Adhesions/Scarring was assessed based on a 4-point scale as follows:
0= No visible granulation/scarring in the FSO
Minimal amount of granulation, scarring or contraction observed but not obstructing the FSO (intervention not warranted)
Moderate amount of obstructive granulation, scarring or contraction present in the FSO (intervention is warranted)
Significant amount of scarring or contraction causing obstruction of the FSO requiring intervention (likely to compromise patency if not removed)</description>
          <units>percentage of evaluable sinuses</units>
          <param>Number</param>
          <units_analyzed>sinus sides</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sinus sides</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation (Propel Nova Cohort)</title>
        <description>The degree of inflammation present in the frontal recess/FSO was evaluated by clinical investigators using a 100-mm VAS ranging from 0 defined as no visible inflammation to 100 defined as severe inflammation, involving extensive erythema, edema, or polyposis.</description>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PROPEL Nova Sinus Implant</title>
            <description>Propel Nova placed in frontal sinus opening following ESS
Propel Nova Sinus Implant: Placement of sinus implant following frontal sinus surgery</description>
          </group>
          <group group_id="O2">
            <title>Sinus Surgery Alone: Cohort 2</title>
            <description>Sinus Surgery only: cohort 2: ESS with standard post-operative care.
Sinus Surgery alone: Sinus surgery only, without implant placement</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation (Propel Nova Cohort)</title>
          <description>The degree of inflammation present in the frontal recess/FSO was evaluated by clinical investigators using a 100-mm VAS ranging from 0 defined as no visible inflammation to 100 defined as severe inflammation, involving extensive erythema, edema, or polyposis.</description>
          <units>100-mm VAS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>sinus sides</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sinus sides</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" spread="24.23"/>
                    <measurement group_id="O2" value="35.6" spread="31.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occlusion/Restenosis (Propel Nova Cohort)</title>
        <description>Patency of the FSO was assessed by clinical investigators endoscopically on a 3-point grading scale as follows:
0=Patent
Restenosed/Partially Occluded
Occluded</description>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PROPEL Nova Sinus Implant</title>
            <description>Propel Nova placed in frontal sinus opening following ESS
PROPEL Nova Sinus Implant.: Placement of sinus implant following frontal sinus surgery</description>
          </group>
          <group group_id="O2">
            <title>Sinus Surgery Only: Cohort 2</title>
            <description>Sinus surgery with standard post-operative care.
Sinus Surgery alone: Sinus surgery only, without implant placement</description>
          </group>
        </group_list>
        <measure>
          <title>Occlusion/Restenosis (Propel Nova Cohort)</title>
          <description>Patency of the FSO was assessed by clinical investigators endoscopically on a 3-point grading scale as follows:
0=Patent
Restenosed/Partially Occluded
Occluded</description>
          <units>percentage of evaluable sinuses</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>sinus sides</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sinus sides</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="6.6" upper_limit="23.2"/>
                    <measurement group_id="O2" value="36.0" lower_limit="25.2" upper_limit="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Propel Mini cohort: 90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PROPEL Mini Sinus Implant</title>
          <description>Propel Mini placed in frontal sinus opening following ESS
PROPEL Mini Sinus Implant.: Placement of sinus implant following frontal sinus surgery</description>
        </group>
        <group group_id="E2">
          <title>PROPEL Nova Sinus Implant</title>
          <description>Propel Nova placed in frontal sinus opening following ESS
PROPEL Nova Sinus Implant.: Placement of sinus implant following frontal sinus surgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <description>not device related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection fungal</sub_title>
                <description>not device related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <description>not device-related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <description>not device related</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>acute sinusitis</sub_title>
                <description>not device related</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>chronic sinusitis</sub_title>
                <description>not device related</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <description>not device related</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>not device related</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>presyncope</sub_title>
                <description>not device related</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <description>not device related</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Stambaugh (VP, Clinical Affairs)</name_or_title>
      <organization>Intersect ENT</organization>
      <phone>650-641-2103</phone>
      <email>jstambaugh@intersectent.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

